For decades, lowering stubborn “bad” cholesterol often meant swallowing statins or rolling up a sleeve for regular injections. Now, there’s a new option that fits in the palm of your hand.
The US Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), the world’s first once-daily pill that blocks PCSK9, a protein that interferes with the body’s ability to remove low-density lipoprotein (LDL), better known as bad cholesterol.
Imagine your liver as the body’s cholesterol vacuum. PCSK9 keeps unplugging it. Lipfendra simply plugs it back in, allowing the liver to clear more LDL from the bloodstream before it can settle inside arteries.
That’s a big deal because high cholesterol is a master of disguise. It usually causes no warning signs until years of plaque buildup narrow the arteries, setting the stage for heart attacks or strokes. For many people, the first clue comes from a routine blood test.
The new medicine is approved for adults with high cholesterol, including those with an inherited form of the condition, and is meant to complement, not replace, healthy eating, exercise and statin therapy.
In two large clinical trials involving more than 3,200 adults already taking the maximum statin dose they could tolerate, Lipfendra slashed bad cholesterol by 56 to 59 percent within 24 weeks compared with placebo.
Its biggest selling point is convenience.
Existing PCSK9 medicines are given by injection every few weeks. Lipfendra delivers the same biological target in a once-daily tablet, a shift experts believe could encourage more patients to stay on treatment.
The most common side effects reported were diarrhea and dizziness, although overall safety was similar to placebo.
Heart disease remains the world’s leading killer, and doctors say preventing clogged arteries is far easier than treating one. While no pill can outrun an unhealthy lifestyle, Lipfendra could make cholesterol control as simple as taking a daily vitamin—one small tablet with the potential to deliver outsized benefits for heart health.
